Liposomal delivery of oligonucleotide therapeutics against antibiotic-resistant bacteria

Marianna Mamusa1, Angels Ruyra Ripoll2, Leopoldo Sitia3, Kostas Hatzixanthis4, Christopher Morris4, Debora Berti1

1 CSGI & Department of Chemistry, University of Florence, Italy
2 School of Biological Sciences, University of East Anglia, Norwich, UK
3 Norwich Medical School, University of East Anglia, Norwich, UK
4 School of Pharmacy, University of East Anglia, Norwich, UK

*mamusa@csgi.unifi.it

Microbial resistance to antibiotics has grown over the last few decades into a serious global threat [1], which must be tackled with innovative therapeutics. We propose to address it by coupling the action of a strong antibacterial, the bolaform cationic surfactant [12-bis-THA]Cl2, with specifically engineered oligonucleotides (TFDs, Transcription Factor Decoys) that can block essential genomic targets in bacteria [2,3]. In order to improve the bioavailability and antibacterial activity of the [12-bis-THA]Cl2/TFD complex, we incorporated it in fusogenic liposomal carriers with controlled composition and morphology. We investigate the effect of the inclusion of the bolaamphiphile in the lipid bilayer and optimize the encapsulation of the oligonucleotide. We characterize the structure of the liposomes by means of dynamic light scattering (DLS), Zeta potential measurements, small-angle X-ray scattering (SAXS), cryogenic electron microscopy (cryo-TEM), UV-Vis absorption and fluorescence spectroscopy. The antibacterial activity and cytotoxicity of these delivery systems are evaluated with in vitro assays, while confocal microscopy experiments on fluorescently labelled samples allow us to assess the delivery of the TFD into model bacterial systems (Figure 1).

Figure 1 Confocal microscopy: liposomes containing the [12-bis-THA]Cl2/TFD complex (green) are delivered into E. coli (red). Insert: schematic representation of the liposomes (blue = POPC/DOPE, red = [12-bis-THA]Cl2, green = TFD.

Acknowledgements Research funded by the People Programme (Marie Curie Actions) of the European Union’s Seventh Framework Programme FP7/2007-2013/ under REA grant agreement n. 612338.